pubmed:abstractText |
Thrombolysis remains the main therapeutic strategy used in stroke, but with a limited use to only a part of stroke patients. A neuroprotective approach would be necessary with a double objective : (1) to serve as an add-on treatment with thrombolysis to improve safety and increase therapeutic window ; (2) to limit infarct area by delaying neuronal death. While numerous molecules failed in clinical trials in stroke, pharmacological development is on-going with pleiotropic drugs targeting both neuronal and vascular parts of neurovascular unit. Another approach targets the functional rehabilitation and the neurorepair using pharmacological ways or cell therapy.
|
pubmed:affiliation |
EA1046, département de pharmacologie médicale, Institut de médecine prédictive et de recherche thérapeutique, Université Lille-Nord de France, Faculté de médecine, Centre hospitalier et universitaire de Lille, 2, avenue Oscar Lambret 59037 Lille Cedex, France. r-bordet@chru-lille.fr
|